Wellness Franchise Opportunities

PharmacyJan, 16 2015

India refuses patent to Gilead for its drug Sovaldi

The patent office noted that a 'molecule with minor changes, in addition to the novelty, must show significantly enhanced therapeutic efficacy' compared with a prior compound.

By WI Bureau

New Delhi: India's patent office has rejected an application from US-based Gilead  Sciencesfor its hepatitis C drug Sovaldi.

The patent application was opposed by Indian drugmaker Natco Pharma, and the Initiative for Medicines, Access & Knowledge, a non-profit organisation. They opposed the application on the grounds that Sovaldi was not a significant improvement compared with an earlier compound developed by another company.

The patent office noted that a 'molecule with minor changes, in addition to the novelty, must show significantly enhanced therapeutic efficacy' compared with a prior compound.

Sovaldi’s $84,000 price tag for a 12-week course in the US has drawn criticism from patient advocates. The rejection will allow the Indian drugmakers to make and sell versions of the drug in country

In September last year, the US pharmaceutical major had announced a licensing deal with seven Indian drugmakers to produce generic versions of Sovaldi that could be sold in 91 countries.

The patent office's decision came amid a growing clamour by healthcare campaigners and doctors to ensure Sovaldi and other new hepatitis C pills are affordable in developing countries.

Image: CorbisImages

Related: Chennai-based Dadha Pharmaceutical launches first online pharmacy ‘NetMeds.com’

Click Here to add Comment
Please add your Comment
Rating
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.

Video

Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.


Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.